Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

New antisense oligonucleotides targeting human SMAD3 from Isis

Feb. 7, 2000

Antitumor epothilone derivatives reported in patent literature by Schering AG

Feb. 4, 2000

COX-2 inhibitor now available for FAP indication

Feb. 4, 2000

Bexarotene now on the market in U.S.

Feb. 4, 2000

InKine files patent for novel antiangiogenic protein

Feb. 4, 2000

AEterna to commence phase III trial of AE-941 in second cancer indication

Feb. 4, 2000

Atrix reports progress in Atrigel leuprolide formulations

Feb. 4, 2000

Incyte patents novel GFMOs for cancer and fibrotic disorders

Feb. 3, 2000

Novel agent for treatment-refractory CIS now under review in Canada

Feb. 3, 2000

Telik initiates clinical testing of first development candidate

Feb. 3, 2000

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 8, 2026.
First measles treatment advances as vaccination rates drop
BioWorld
Scientists at the La Jolla Institute for Immunology have identified and characterized human antibodies that neutralize the measles virus by blocking its entry...
Infensa Bioscience identifies new ASIC blockers
BioWorld Science
Infensa Bioscience Pty Ltd. has patented new acid-sensing ion channel 1 (ASIC) blockers potentially useful for the treatment of stroke, among others.
Hantavirus is ‘sentinel’ more than acute pandemic threat
BioWorld
News of eight infections and three deaths so far due to an emerging zoonotic virus has brought back unhappy memories of the early days of SARS-CoV-2. At a press...
Italy’s Angelini pays $4.1B cash for rare disease specialist Catalyst
BioWorld
Italian family-owned Angelini Pharma SpA is making its first move into the U.S. market, acquiring rare diseases specialist Catalyst Pharma Inc. in an all-cash...